Allogene Therapeutics
Price & Volume
Stats
See moreOpen | $2.87 |
Previous Close | $2.91 |
Day Range | $2.81-$2.87 |
52W Range | $2.01-$5.77 |
Market Cap | $608.5M |
Shares Short | 38M |
Financials
See moreRevenue (12 Mos) | $65,000 |
Revenue Growth (YoY) | -26.7% |
Gross Profit (12 Mos) | $243,000 |
Diluted EPS | -$1.59 |
News
See moreYahoo Finance • 11 months ago
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript
Yahoo Finance • 11 months ago
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Yahoo Finance • 11 months ago
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Yahoo Finance • 11 months ago
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
About
CEO | Dr. David D. Chang M.D., Ph.D. |
CFO | Mr. Geoffrey M. Parker |
Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 232 |
